Next Article in Journal
Scoring Amino Acid Mutations to Predict Avian-to-Human Transmission of Avian Influenza Viruses
Next Article in Special Issue
Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development
Previous Article in Journal
Cu(II) Complexes of 4-[(1E)-N-{2-[(Z)-Benzylidene-amino]ethyl}ethanimidoyl]benzene-1,3-diol Schiff Base: Synthesis, Spectroscopic, In-Vitro Antioxidant, Antifungal and Antibacterial Studies
Previous Article in Special Issue
Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessFeature PaperReview
Molecules 2018, 23(7), 1583;

Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines

Department of Chemistry, University of Florida, 214 Leigh Hall, Gainesville, FL 32611, USA
Author to whom correspondence should be addressed.
Academic Editors: Paul Kovac, Peng Xu and Helene Pfister
Received: 11 June 2018 / Revised: 25 June 2018 / Accepted: 28 June 2018 / Published: 29 June 2018
(This article belongs to the Special Issue Conjugate Vaccines from Carbohydrate Antigens)
Full-Text   |   PDF [3227 KB, uploaded 29 June 2018]   |  


Many malignant cell surface carbohydrates resulting from abnormal glycosylation patterns of certain diseases can serve as antigens for the development of vaccines against these diseases. However, carbohydrate antigens are usually poorly immunogenic by themselves, thus they need to be covalently coupled with immunologically active carrier molecules to be functional. The most well established and commonly used carriers are proteins. In recent years, the use of toll-like receptor (TLR) ligands to formulate glycoconjugate vaccines has gained significant attention because TLR ligands can serve not only as carrier molecules but also as built-in adjuvants to form fully synthetic and self-adjuvanting conjugate vaccines, which have several advantages over carbohydrate-protein conjugates and formulated mixtures with external adjuvants. This article reviews recent progresses in the development of conjugate vaccines based on TLR ligands. Two major classes of TLR ligands, lipopeptides and lipid A derivatives will be covered with more focus on monophosohoryl lipid A (MPLA) and related analogs, which are TLR4 ligands demonstrated to be able to provoke T cell-dependent, adaptive immune responses. Corresponding conjugate vaccines have shown promising application potentials to multiple diseases including cancer. View Full-Text
Keywords: conjugate vaccine; carrier molecule; adjuvant; toll-like receptor ligand; lipopeptide; monophosphoryl lipid A conjugate vaccine; carrier molecule; adjuvant; toll-like receptor ligand; lipopeptide; monophosphoryl lipid A

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Li, Q.; Guo, Z. Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines. Molecules 2018, 23, 1583.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top